Overview
Ditch Labs is a pioneering company in the digital health sector, headquartered in Montréal, Québec, Canada. Founded in January 2020, the company is dedicated to revolutionizing nicotine addiction treatment through a combination of AI-driven behavioral therapy and the innovative DitchPen® vaporization device. This patent-pending medical vaporizer delivers controlled dosages of nicotine, gradually tapering them to support effective addiction treatment. Ditch Labs targets nicotine addiction, a leading cause of preventable death, as part of its mission to transform public health.
Key Personnel
Leadership Team:
- Laurent Laferrière, Co-Founder & CEO: Leads the company's strategic direction and secures key partnerships and investments, leveraging extensive entrepreneurial experience.
- Olivier Bourbonnais, Co-Founder & CTO: Oversees technological development of Ditch's digital therapeutics, focusing on innovative addiction treatment solutions.
- Christelle Luce, PhD, Chief Scientific Officer: Directs scientific research and clinical strategies, offering expertise in psychology and addiction.
- Moishe Liberman, MD, PhD, FRCSC, FACS, Chief Medical Officer: Since 2022, he has strengthened the clinical capabilities of Ditch Labs with his background in minimally invasive thoracic surgery.
Team Composition:
The multidisciplinary team includes entrepreneurs, engineers, data scientists, physicians, psychologists, and pharmacologists, ensuring comprehensive development and execution of their digital therapeutic solutions.
Key Offerings
Ditch Labs' flagship product is a patent-pending vaporization platform technology complemented by a mobile application for behavioral modification. This dual hardware-software solution provides personalized, AI-driven behavioral therapy to improve public health outcomes and is uniquely positioned in the market for addiction treatment. While initially targeting nicotine dependence, the platform is designed to extend its applicability to a broader range of substance addiction challenges.
Recent Developments and Financial Highlights
- July 12, 2023: Ditch Labs secured $3.25 million in seed funding. This milestone reflects investor confidence in the company’s potential to innovate the smoking cessation landscape.
- The Québec government granted the company $350,000 through MEDTEQ+ and PromptInnov, highlighting its strategic importance in healthcare innovation.
- Ditch Labs has raised a total of $2.65 million in initial funding rounds from key investors including MEI, MEDTEQ, and PromptInnov.
Strategic Developments
In December 2023, Ditch Labs expanded its intellectual property portfolio by acquiring IP assets from Enovap SAS, a French company known for its medical vaporization technology. This strategic acquisition enhances Ditch Labs’ capabilities in developing advanced solutions for nicotine addiction and other potential therapeutic applications.
Market Impact and Position
Operating in a competitive landscape of digital therapeutic companies focusing on addiction treatment, Ditch Labs differentiates itself through unique integration of AI and proprietary vaporization technology. Recognized alongside startups like Pelago and Affect Therapeutics, Ditch Labs is a pioneering force in digital health solutions for nicotine addiction.
Future Outlook and Prospects
As a clinical-stage healthtech company, Ditch Labs is well-positioned to expand its influence in the digital health domain through robust innovation and development of product offerings. The focus on AI-driven therapies to address complex addiction challenges reflects a commitment to transforming public health policies and treatment paradigms. This innovation not only promises growth in nicotine addiction treatment but also potential applications across various substance use disorders.
Ditch Labs aims to set a new global standard in addiction treatment while expanding its market reach through continuous innovation and technological advancement.
